However, also the dose of the drug seems to impact on the response to treatment; at this regard IFNα at a higher dose in a cohort of 31 CALR-positive ET patients induced hematologic responses in all patients with a median reduction of CALR mutated allele burden from 41% to 26% [133]. This evidence concerns the gene CALR and essential thrombocythemia.